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Abstract: More than 50 million Muslims throughout the world with type 2 diabetes mellitus 
(T2DM) fast for one lunar month (Ramadan) each year. Health care providers within and out-
side the Muslim world need to be aware of the nature of these partial days of fasting and their 
risks (and potential benefits) to people with T2DM, and need to provide Ramadan-adjusted 
diabetes care. Hypoglycemia during the fasting days represents the greatest health risk for these 
patients; hence, diabetes-related pharmacotherapy needs to be tailored and adjusted with this 
risk in mind. With limited trial data available, this review proposes practical modifications to 
the usual pre-Ramadan antidiabetic regimens that are based on pathophysiological principles, 
clinical trial evidence (where available), expert opinion, and extended practical experience. 
Individualization of care is paramount in this regard to take into consideration the patient and 
societal, cultural, and economic variables.
Keywords: type 2 diabetes mellitus, Ramadan, fasting, hypoglycemia, oral antidiabetic agents, 
insulin
Introduction
Followers of Islam accounted for nearly a quarter (1.7 billion) of the world’s population 
(7 billion) in 2011.1 They inhabit the Middle East, North Africa, and central and east 
Asia. They also form a significant minority in almost every nation.2 Hence, health care 
issues peculiar to Muslims will inevitably be encountered worldwide, and health care 
providers and societies will have to deal with and accommodate their health needs.
Ramadan is the ninth month of the lunar calendar year.3 The lunar calendar is the 
focal point of religious activities, although the Gregorian calendar has been adopted 
(as in the rest of the globe) for business. Annual calendars that combine both the lunar 
and the Gregorian systems are available.
For all adults, fasting during the month of Ramadan on an annual basis (detailed 
below) is one of five pillars of Islamic practices, which also include the following: 
Shahadah, meaning faith in one God and faith in the prophet (Mohamed, and all other 
prophets); Salah, meaning five prayers a day; Zakah, meaning 2.5% annual capital 
gain deduction, taken from the rich and given to the poor; Haj, meaning one pilgrim 
visit to Mecca in a lifetime, whenever possible; and Sawm, meaning Ramadan fasting, 
as discussed below.4
The fast includes abstinence from eating, drinking, and smoking only from sunrise 
to sunset. Thus, it represents only a partial day fast. The fasting hours vary from 
10 hours in a temperate climate to 20 hours or more in hot climates, depending on the 
geographical location and time of Ramadan in the seasonal cycle. The lunar months 
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shift by 13–15 days annually on the Gregorian calendar. 
The starting age of fasting varies between men and women 
according to the definitions of “responsible maturity” among 
the various religious schools within the Islamic faith. In 
general, girls start fasting earlier (at 9–12 years) than boys 
(at 13–15 years). Information related to fasting for Ramadan 
is shown in Figure 1.
Muslims are globally widespread. Some are privileged 
enough to have type 2 diabetes mellitus (T2DM) management 
that involves health care professionals who are aware of the 
fasting practice, adjustments to their therapeutic regimens to 
suit their clinical profiles, and provision of Ramadan-specific 
diabetes education.5 In contrast, patients in poor countries 
or deprived and remote communities face huge challenges 
related to the adequacy of and access to health care, availabil-
ity of medications (especially insulin), and storage problems 
(given that off-grid communities often have no refrigeration 
facilities). This is in addition to high illiteracy rates and dif-
ficulties in providing the necessary Ramadan-focused diabetes 
education. These considerations and other relevant facts are 
detailed in this clinical review, which is aimed at practicing 
health care professionals caring for Muslims with T2DM who 
are intending to fast during the month of Ramadan.
Methodology
A Medline search for clinical trials that evaluated antidiabetic 
agents during Ramadan fasting in people with T2DM was 
undertaken. The following keywords were used: “type 2 
diabetes mellitus”, “Ramadan”, “fasting”, “oral antidiabetic 
agents”, and “insulin”. A total of 10 trials satisfied the criteria 
of a direct head-to-head comparison of two (or more) antidi-
abetic agents with preintervention-specified endpoints. Nine 
of the trials were prospective and controlled, and one was 
a retrospective audit. All were open-labeled and industry-
sponsored. These trials are described in a later section of this 
review. The conclusions drawn from these trials, in addition 
to expert opinions and published individual author opinions, 
support the synthesis presented in this review of the currently 
available literature pertinent to the management of adults with 
T2DM who intend to fast during the month of Ramadan.
Metabolic adaptations to partial  
day fasting
In otherwise healthy individuals without diabetes, glucose 
concentrations fall during fasting, which signals reduced 
insulin production by islet beta cells. This is coupled with 
enhanced production of glucagon by alpha cells and of 
catecholamines.6 These changes lead to an accelerated 
breakdown of glycogen stored in the liver. At an estimated 
rate of 8–10 grams of glycogen consumed per hour, hepatic 
glycogen stores (totaling 70 grams on average) are depleted 
within the first 10–12 hours of fasting. Antecedent with the 
enhanced glycogenolysis is augmented gluconeogenesis. 
Low levels of insulin also lead to increased fatty acid release 
from adipocytes. These fatty acids can be oxidized to gener-
ate ketones that are utilized as alternative fuels by all of the 
body organs, thus sparing glucose to be utilized by glucose-
dependent organs, ie, the brain and erythrocytes.7
This intricate balance between levels of circulating insulin 
and the counter-regulatory hormones, which maintain glucose 
•   Time: Days 1–29/30 of the lunar month. In 2012, this will be the July 15 to August 14. Each year, Ramadan advances by 13–14 days 
on the Gregorian calendar. Ramadan will occur during the hot summer months over the next decade in most of the Muslim world.
•   Duration: Fasting starts 75 minutes before sunrise and ends 15 minutes after sunset (or immediately at sunset in some sects). This results 
in a fast for 11–12 hours in equatorial countries and 16–20 hours or more in countries away from the equator (eg, Scandinavia).
•   Fasting day: Abstaining from all eating, drinking, and smoking. Ingestion of any material including medications orally or parenterally 
is also prohibited.
•   Who fasts: All mature (religiously responsible) adults (females above 9 years and males above 15 years of age) participate in the fast.
•   Exemptions: Those who are ill (if fasting is expected to inflict significant harm), travelers, and menstruating females are exempted 
from the fast.
•   Food consumption: Usually, two main meals are taken. One meal is at sunset (Iftar), which is usually communal (gatherings at 
mosques, clubs, streets, or family) with calorie-dense foods. The second meal is 2 hours before sunrise (Suhur), which is composed of 
slowly absorbed foods, such as beans, to sustain the individual during the long fasting hours of the day. Snacks are usually consumed 
between these meals. These patterns are variable among different cultures.
•   Work, school, and leisure activities: In some (but certainly not all) predominantly Muslim countries, work and school hours are 
shortened to 5–6 hours. Nights are usually spent socializing, entertaining, and praying. The hours of the day are split between sleep-
ing and working or attending school. Sports and physical activity are usually carried out in the evenings. Many Muslim countries and 
certainly all non-Muslim countries, however have no such allowances for Ramadan-related practices, and life proceeds as usual. The 
month of Ramadan is viewed as a month of celebration, sharing, giving, and soul searching. It is an opportunity to be close to God, 
society, family, and self.
Figure 1 Fact sheet on the fasting month of Ramadan.
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levels within a physiological range, is disturbed in people with 
T2DM. This is due to pathophysiological derangements in 
both insulin secretion and sensitivity, depending on the stage 
of the disease. Initially insulin insensitivity is predominant, 
with a resultant compensatory hyperinsulinemia but maintain-
ing relative functional hypoinsulinemia.8 With progressive 
beta cell decline, there is continuing insulin deficiency, with 
eventual insulin depletion in the latter stages of the disease. 
Insulin sensitivity and/or secretion are also influenced by 
the pharmacological agents used in management of T2DM. 
Insulin therapy augments fasting hypoglycemia, while counter-
regulatory responses might be curtailed in the advanced stages, 
leading to profound and prolonged hypoglycemia.9
Risks of fasting in people with T2DM
Hypoglycemia
As discussed above, fasting leads to reduced glucose 
levels that invoke compensatory mechanisms to prevent 
hypoglycemia. However, in the presence of certain antidiabetic 
agents that promote insulin secretion, or more commonly with 
insulin provision therapy, hypoglycemia may ensue, with 
potentially serious or even life-threatening consequences.10 
In nonfasting people with T2DM, rates of hypoglycemia and 
related deaths are perceived to be lower (percentage unknown) 
than those encountered by people with T1DM (2%–4% 
mortality).11 In people with T2DM, the recent EPIDIAR 
(Epidemiology of diabetes and Ramadan 1422/2001) audit 
study showed that fasting during Ramadan increased the risk 
of severe hypoglycemia requiring hospitalization by seven-
fold (from 0.4 to 3 events per 100 people per month).12 This 
is expected to be an underestimate if significant hypoglycemia 
requiring third party assistance is included in the analysis. 
Predictors of an increased frequency of severe hypoglycemia 
were medication (insulin or oral hypoglycemic agents) dose 
changes and drastic changes in lifestyle during Ramadan. In 
another recent five-country observational study, the incidence 
of hypoglycemia was 20% in sulfonylurea-treated patients 
who were fasting for Ramadan (range 14%–26%).13 These 
points are pivotal for the management of people with T2DM 
who are fasting for Ramadan, and need to be addressed when 
reviewing and adjusting their antidiabetic therapy.
Hyperglycemia
The link between glycemia and future long-term complica-
tions (both microvascular and macrovascular) in T2DM was 
well established by the UK Prospective Diabetes Study.8 
However, short-term (eg, 4-week duration) hyperglycemia 
was not established as a contributor to long-term morbidity 
or mortality. It is still prudent to aim to avoid overt and/or 
symptomatic hyperglycemia during Ramadan to prevent its 
catabolic effects and the annoying accompanying features 
of polyuria, polydipsia, polyphagia, and visual disturbances. 
In the abovementioned EPIDIAR study,12 the incidence of 
severe hyperglycemia requiring hospitalization increased 
by five-fold (from 1 to 5 events per 100 people per month). 
Excessive food intake during the nonfasting eight hours (note 
that most patients actually gain weight during Ramadan)13 
and reductions in the dosages of antidiabetic agents 
(to avoid daytime fasting hypoglycemia) may contribute to 
the increased incidence of hyperglycemia by several-fold. 
Glycemic control has been reported to improve, remain 
unchanged, and even deteriorate during Ramadan fasting in 
people with T2DM.14–16
Hypovolemia and thrombosis
Prohibition of fluid intake during the fast is a potential cause 
of volume depletion, especially if the fasting is prolonged, 
and would be exacerbated by a hot climate and strenuous 
physical activity. Osmotic diuresis, which is a result of hyper-
glycemia, worsens the volume deficit and leads to a loss of 
electrolytes.17 The ensuing hypovolemia leads to orthostatic 
hypotension, which is worsened by pre-existing autonomic 
neuropathy, that brings about syncope, falls, and injuries, 
with potential fractures and wounds.18 The hypercoagulable 
state of diabetes is made worse by contraction of the intra-
vascular space that in turn enhances blood viscosity. These 
derangements contribute to the increased risk of thrombosis 
and stroke.19 Hyperosmolar states can be predicted to occur 
in elderly patients with underlying comorbidities, especially 
those with poor dietary intake or superadded infections (par-
ticularly urinary tract, pneumonia, and skin wounds) in the 
absence of adequate health care. However, there are no data 
on mortality due to fasting in people with T2DM.
Management of T2DM during 
Ramadan fasting
Goals
The overriding consideration for the management of 
patients with T2DM during the fasting month of Ramadan 
is patient safety. Effort has been focused on avoidance of 
acute metabolic derangements, including hypoglycemia, 
overt/symptomatic hyperglycemia, hyperosmolar states, 
hypovolemia, and heat exhaustion (in hot climates, especially 
with strenuous physical activity). Diabetic ketoacidosis 
is rarely encountered in people with T2DM, unlike those 
with T1DM.
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Although all of the effort should be expended to achieve a 
stable glycemic state, an insistence on tight glycemic control 
is not warranted and may only exacerbate (and even induce) 
the abovementioned potential risks that are associated 
with fasting. Individualized, patient-tailored advice should 
be based on the best available evidence-based practices. 
This should be backed by clinical judgment and take into 
consideration the patient’s clinical profile, available health 
care resources, socioeconomic variables, and cultural and 
religious beliefs and practices. Steps towards attainment 
of therapeutic goals and targets in people with T2DM and 
for helping patients with tools for better adherence to and 
compliance with therapeutic regimens have recently been 
proposed. These are mostly derived from clinical com-
monsense but are also supported by recently reported trial 
evidence.20 These general principles are also applicable to 
the management of people with T2DM during Ramadan 
fasting.21–23 Figure 2 proposes steps toward improving the 
management of people with T2DM who are fasting for 
Ramadan. Figure 3 depicts an algorithm for suggested 
adjustments to pre-Ramadan therapeutic regimens.24
Ramadan-focused diabetes education  
for people with T2DM
A recent UK study showed that rates of baseline hypo-
glycemic events were reduced by attending a structured 
Ramadan-focused diabetes education program designed for 
people with T2DM (n = 57) by approximately 50% (from 
9 events at baseline to 5 events at the end of Ramadan), while 
the rates increased four-fold in the group that did not attend 
the program (n = 54, from 9 events at baseline to 36 events 
by the end of Ramadan).25
Educational sessions can be provided by health care 
professionals to people with T2DM who are intending to 
fast for Ramadan individually or in groups, and preferably 
several weeks before Ramadan to provide adequate time for 
the patients and their families or caregivers to prepare for the 
fasting month. In underprivileged communities, public places 
(schools, mosques, public gatherings, and charities) can be 
used for both education and providing resources, including 
medications, glucose monitoring, and food packages, which 
is befitting of the spirituality and atmosphere of giving and 
sharing of the holy month. Sessions should include advice 
on the following:
•	 Risks of fasting
•	 Meal planning and food choices to avoid post-Iftar (sunset 
meal) hyperglycemia and fasting day hypoglycemia
•	 Timing and dosing of medications
•	 Physical activity during both the fed and fasting states 
(especially for strenuous jobs, hot climates, and prolonged 
fasting hours)
•	 Home capillary glucose monitoring
•	 Response to hyperglycemia
•	 Response to fasting hypoglycemia and when to break 
the fast. In general, patients are advised to break 
the fast if their blood glucose is less than 70 mg/dL 
(3.9 mmol/L) in the early fasting hours because hypo-
glycemia can only worsen, especially in patients taking 
insulin and/or sulfonylureas. The fast should also be 
terminated if the blood glucose is less than 60 mg% 
(3.3 mmol/L) at any time of the day. No such limits 
are established for hyperglycemia because patients may 
remain asymptomatic in the face of markedly elevated 
glucose concentrations.
Pharmacotherapy for glycemia  
in fasting people with T2DM
Based on the pathophysiological understanding of the pro-
gressive nature of T2DM from a predominance of insulin 
resistance, which is reflected in fasting euglycemia and 
postprandial hyperglycemia, insulin sensitizers (metformin 
and glitazones) are viewed as baseline therapies at this stage 
of the disease.26 Alpha-glucosidase inhibitors are also used 
at this stage, but to a lesser extent. This is due in part to their 
limited efficacy (average glycosylated hemoglobin [HbA1c] 
reduction 0.5%) and, to a larger extent, their gastrointestinal 
side effects, namely flatulence.27 With a progressive islet 
beta cell decline, which is evidenced by fasting hyperg-
lycemia and worsening postprandial glucose excursions, 
the insulin secretagogues (glinides and sulfonylureas) are 
introduced.28 This is eventually followed by the need for 
insulin provision therapy for what is termed the “secondary 
•   Provision of Ramadan-specific diabetes education (both health 
care providers and patients, their families, and concerned 
organizations)
•    Pre-Ramadan review of patient’s clinical profile including 
  glycemic control and diabetes-unrelated comorbidities
•    Making necessary Ramadan-specific therapeutic adjustments, 
as detailed in the text and summarized in Figure 3 and Tables 1 
and 2
•    Provision of continuing care before, during and after Ramadan, 
including home glucose monitoring and ensuring access and 
availability of medications.
Figure 2 Proposed steps for glycemic control during Ramadan fasting in people with 
type 2 diabetes mellitus.
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sulfonylurea failure” stage.29 Early insulin introduction in 
patients who initially present with marked and/or symptom-
atic hyperglycemia (islet beta cell rescue from glucotoxicity) 
has gained popularity.30 Figure 4 depicts principles for the 
judicial use of pharmacological antidiabetic agents during 
Ramadan fasting.
Early introduction of basal insulin, in addition to insulin 
sensitizers, has also been advocated in recent treatment 
guidelines as an alternative to the addition of sulfonylureas 
as a second-line strategy for the management of glycemia 
in T2DM.31 This is intensely debated, partly due to a lack of 
trial evidence on the end-organ benefit and mostly due to a 
reluctance to introduce insulin early on in a chronic disease. 
This reluctance is thought to be due to the significant impact 
on the patient’s lifestyle and quality of life.32
The recent introduction of an incretin-based therapy and, 
to a lesser extent, amylin-based agents and sodium-glucose 
cotransporter 2 inhibitors, has added to the armamentarium 
of antidiabetic agents, especially in view of their weight 
gain-sparing effect and proclaimed ability to preserve islet 
beta cells.33–35 Figure 5 summarizes the mode and site of 
action of the commonly used antidiabetic agents in relation 
to their hypoglycemic risk and their weight gain-sparing 
potential.24
Adjust current regimen:
1. As per Table 1 for
    patients on non-insulin
    agents
2. As per Table 2 for
    patients with T2DM on 
    insulin
Moderate/High risk** Low risk*
Continue same regimen
Acceptable control Poor control
Adjusted Ramadan
regimen
Acceptable control Poor control
Current regimen
Consider:
1. Dietary review and advice
2. Exercise and physical activity
    review and advice
3. Address compliance issues,
    if any
4. Intensify HBGM
5. Adjust regimen (see text
    and corresponding tables)           
Glycemia
Glycemia
Assess risk for
hypoglycemia
Figure 3 Proposed algorithm for pre-Ramadan review and adjustments of lifestyle and therapeutic regimens.
Adapted and modified from AlMaatouq.24 *Stable glycemic control with no major comorbidities on metformin, glitazones, alpha glucosidase inhibitors and incretin modulators. 
**Fluctuating glycemia, major comorbidities esp. renal/hepatic insufficiency and/or use of insulin and sulfonylureas.
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Antidiabetic agent with low risk
for hypoglycemia and neutral
or favorable weight changes
Liver
Metformin
Insulin sensitizers
Muscle
Incretin system modulators
Endogenous
Exogenous
insulin
Insulin
G
l
i
t
a
z
o
n
e
s
Glucagon
A cell
B cell
GlinidesS ulfonylureas
Gut
Pancreas
Insulin secretagogues
α-glucosidase inhibitors
Antidiabetic agent with 
potential for hypoglycemia 
and weight promotion
Figure 5 Site and mode of action of the most commonly used antidiabetic pharmacological agents, classified by their hypoglycemic risk potential and weight gain/loss 
characteristics.
Adapted and modified from AlMaatouq.24
•   Consider regimen adjustments in the pre-Ramadan period to avoid last-minute drastic changes that might not be efficacious or that 
might lead to unexpected side effects.
•    Consider agents with the least potential for hypoglycemia (in the absence of contraindications, as detailed in the text and illustrated 
in Figure 5) wherever possible. These include the following:
  •    Insulin sensitizers (metformin, a biguanide, and pioglitazone, a thiazolidinedione)
  •    Incretin-based agents, such as the dipeptidylpeptidase-4 inhibitors and the glucagon-like peptide-1 mimetics
  •   Alpha-glucosidase inhibitors, such as acarbose and voglibose.
•    These should be utilized as baseline agents. Consideration should be given to switching to these agents and/or adding them   
to the pre-existing regimen.
•  Choose agents with complementary actions that are pathophysiologically based.
•    Consider agents that can be used only once daily, eg, long-acting metformin preparations or pioglitazone, to improve compliance.
•   A simpler regimen is better. Neutral protamine Hagedorn insulin in combination with metformin taken at Iftar might be just as efficacious 
and have a better adverse profile potential and improved compliance compared with more elaborate regimens.
•  Specific noninsulin regimen adjustments are detailed in the text and summarized in Table 1.
•  Specific insulin regimen adjustments are detailed in the text and summarized in Table 2.
•  Consider readily available agents that are less costly as long as the efficacy and safety are ensured.
•  Review regimen before, during, and after Ramadan and make necessary adjustments, see Figure 3.
Figure 4 Principles of antihyperglycemic therapeutic regimen adjustments in people with type 2 diabetes mellitus who are fasting for Ramadan.
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Adjustments of tools for glycemic 
control during Ramadan fasting
Metformin
Although the risk of severe hypoglycemia due to met-
formin in nonfasting patients is rare,36 there are no data on 
patients who are fasting for Ramadan and taking metformin. 
Because there are only two main meals in Ramadan, the 
metformin dose should be split into two thirds at Iftar and 
one third at Suhur. For example, for patients taking 850 mg 
of metformin three times a day, their medication should 
be adjusted to 1700 mg at Iftar and 850 mg at Suhur. For 
patients on extended-release metformin preparations, the 
dose should be taken once at Iftar.
Thiazolidinediones
Pioglitazone is currently the only nonrestricted agent in 
use from this class due to the unfavorable safety profile of 
rosiglitazone.37 Hypoglycemia is not usually associated with 
this class of agents, but hypoglycemia due to other accom-
panying agents can be exacerbated. If pioglitazone is being 
considered as an addition to or a substitution of other agents 
in the pre-Ramadan review, then this needs to be done several 
weeks before Ramadan because 2–4 weeks are required for 
its antiglycemic action to take full effect. The full dose (the 
author uses a maximum dose of 30 mg) is given once daily 
at Iftar during Ramadan.
incretin-based therapy
Recently introduced modulators of the incretin system include 
the dipeptidylpeptidase-4 inhibitors and the glucagon-like 
peptide receptor agonists. The dipeptidylpeptidase-4 inhibitors 
include oral agents that are currently available in clinical 
practice, ie, sitagliptin, vildagliptin, alogliptin, and saxagliptin. 
These agents are not associated with hypoglycemia but may 
increase the hypoglycemic effect of other agents, such as 
sulfonylureas, glinides, and insulin. Vildagliptin + metformin 
was associated with less hypoglycemia than gliclazide + 
metformin in patients with T2DM during Ramadan in a retro-
spective data audit.38 A recent prospective study of more than 
1000 patients with T2DM who fasted during Ramadan found 
that the risk of hypoglycemia associated with a vildagliptin-
based regimen (vildagliptin 100 mg once daily) was lower 
than that of a sulfonylurea-based regimen (both with and 
without metformin).39 The glucagon-like peptide receptor 
agonists (incretin mimetics) include the short-acting (half-life 
2 hours) exenatide and once-daily liraglutide. Exenatide can 
be dosed before the two main meals and is not associated with 
significant effects on fasting glucose. Liraglutide is dosed once 
daily, irrespective of the timing of meals, and has significant 
antiglycemic effects with fasting. Both agents require dose 
titration over a period of 2–4 weeks for their maximum effects 
to be seen, and both induce nausea in over half of patients.40 
Currently, no published studies have evaluated these agents 
during Ramadan.
Alpha-glucosidase inhibitors
Acarbose, voglibose, and miglitol retard glucose absorption 
(thus modifying insulin secretion) by inhibiting the action 
of intestinal brush border alpha-glucosidases. Although the 
risk of hypoglycemia is low with these agents, their use 
is limited in clinical practice due to the high frequency of 
gastrointestinal side effects, mainly flatulence, and their 
subdued reduction of HbA1c ($0.5%), which necessitates the 
addition of other antiglycemic agents.27 No clinical studies 
have evaluated this class of drugs during Ramadan. There 
is no need for dose titration, and it is advisable to take these 
agents during the first bite of each main meal.
Short-acting insulin secretagogues  
and sulfonylureas
Because of their ultrashort duration of action, the short-
acting insulin secretagogues (glinides, ie, repaglinide and 
nateglinide) can be used before the main two meals in 
Ramadan. Repaglinide was found to cause less hypoglycemia 
(0.03 versus 0.05) compared with glibenclamide in patients 
with T2DM who fasted during Ramadan.41 However, there 
was no difference in HbA1c reduction, fructosamine levels, or 
weight change in another small study that compared repaglin-
ide, glimepiride, and gliclazide, and there was only one docu-
mented hypoglycemic event in a patient on glimepiride.42
Due to their efficacy (HA1c reduction . 1%), widespread 
use, extended global experience, low cost, and the absence 
of evidence for an adverse profile, sulfonylureas are com-
monly used as a second-line therapy after metformin.43 The 
potential for hypoglycemia has been documented in many 
studies, but fasting during Ramadan has not been shown to 
exacerbate this in several studies.44,45
In general, it is recommended to give two thirds of the 
daily dose of sulfonylureas at Iftar and one third at Suhur. 
It is also recommended to avoid long-acting sulfonylureas, 
such as chlorpropamide and tolbutamide, to avoid protracted 
hypoglycemia in both fasting and nonfasting people with 
T2DM. No studies have been carried out on the recently 
introduced modified-release formulations, such as gliclazide 
modified release, during Ramadan. Table 1 summarizes the 
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proposed alterations in noninsulin antidiabetic agents during 
the fasting month of Ramadan.
insulin therapy
Insulin therapy during Ramadan fasting represents a challenge 
to both patients with T2DM and health care providers alike 
due to the potential for significant hypoglycemia, albeit 
this is less frequent (and rarely life-threatening) than that 
encountered in patients with T1DM.6
If insulin is to be introduced, this should be done several 
months before Ramadan to allow time to titrate the type(s) 
of insulin, dosage, and timing, as guided by the patient’s 
lifestyle, meal patterns, costs, and availability.24 In general, 
the simplest regimen to achieve good fasting glycemic control 
is recommended as a starting point. This could be achieved 
with nocturnal basal insulin (alone or in combination with 
an insulin sensitizer, such as metformin, an incretin modu-
lator, or an alpha-glucosidase inhibitor). This can later be 
augmented with short-acting insulin to cover postprandial 
glycemic excursions.
Several approaches to insulin regimen adjustments 
during Ramadan fasting have been postulated in recent 
reviews, which were based primarily on expert opinion and 
occasionally on small clinical trials. Table 2 summarizes the 
suggested adjustments to insulin regimens (types and doses) 
during Ramadan fasting.
Single basal insulin
Patients are advised to reduce the single basal insulin dose 
(preferably taken at Iftar) empirically by 20%–30% to 
avoid daytime hypoglycemia, especially if the insulin is in 
combination with glinides or sulfonylureas. The dose can 
later be adjusted during Ramadan depending on the daytime 
fasting glycemia profile. A multicenter, observational, pro-
spective study in fasting patients on metformin in combination 
with glimepiride before Iftar (n = 21), repaglinide given with 
both meals, or glargine given at 10 pm, showed a nonsignifi-
cant increase in rates of hypoglycemia for the glimepiride 
group (14.3%).46 In nonfasting patients, several studies 
failed to show significant advantages in glycemic control 
(HgA1c) or the rates of hypoglycemia when nonanalog insulin 
preparations (neutral protamine Hagedorn, Humulin N; Eli 
Lilly; Indianapolis, IN) were compared with the recently 
introduced and more costly analog preparations (glargine and 
detemir) when used in combination with oral agents.47,48 How-
ever, no similar studies have been carried out in people with 
T2DM who were fasting for Ramadan. Patients on a single 
premixed insulin regimen (alone or in combinations with 
oral agents) are advised to reduce their dose empirically by 
20%–30%, which should be taken before Iftar (evening meal). 
The dose can be adjusted according to post-Iftar glycemic 
excursions and fasting day glycemia levels. This regimen has 
Table  1  Adjustments  of  noninsulin  antidiabetic  regimens  in 
people with type 2 diabetes who are fasting for Ramadan
Regimen Iftar (sunset)  
meal
Suhur (predawn)  
meal
Metformin Two thirds of dose One third of dose
Pioglitazone and  
other glitazones
Full dose with  
no change
None
Acarbose and other  
a-glucosidase inhibitors
Same dose Same dose
Dipeptidylpeptidase-4  
inhibitors
Same dose Same dose
GLP, glucagon-like  
peptide-1 receptor  
agonists
Exenatide: same dose 
Liraglutide: full dose
Exenatide: same dose 
Liraglutide: none
Glinides Same dose Same dose
Sulfonylureas Glibenclamide:  
same dose 
Gliclazide: same dose
Glibenclamide: half 
dose or none 
Gliclazide: same dose
Table  2  insulin  regimen  adjustments  in  people  with  type  2 
diabetes who are fasting for Ramadan
Regimen Suggested adjustments
Single basal  
(or premixed)  
insulin
Take insulin before dinner (iftar) 
Empirical reduction of dose by 30% (if blood 
glucose is well controlled pre-Ramadan) 
Adjust dose as per home blood glucose 
monitoring to avoid daytime (especially late  
in the day/pre-iftar) hypoglycemia
Twice daily  
premixed  
(or basal) insulin
Take the usual larger dose at iftar 
Reduce the smaller dose (usually before dinner) 
by 30% to coincide with pre-Suhur/early 
morning meal 
Adjust doses to avoid early morning and  
pre-sunset hypoglycemia
Twice daily premixed  
insulin plus bolus  
insulin before lunch
Take the usual larger dose at iftar 
Omit the bolus dose unless the patient’s eating 
profile includes a large meal at midnight
Basal-bolus insulin Basal insulin to be taken pre-iftar without dose 
change 
Bolus dose taken before iftar may need to be 
augmented 
Bolus dose taken before Suhur is either 
omitted or reduced to avoid daytime 
hypoglycemia
Premeal boluses Adjust the pre-iftar dose to avoid postprandial 
hyperglycemia 
Adjust the pre-Suhur dose to avoid daytime 
hypoglycemia
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
116
AlMaatouqDiabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2012:5
Management of T2DM during 
Ramadan in underprivileged 
communities
Most reviews of this topic have been directed towards the 
provision of diabetes care to people living in (or migrating to) 
socioeconomically advantaged societies.54–57 However, the 
fact remains that a significant majority of Muslims live in 
underprivileged societies with primitive or poorly structured 
health care and limited access and resources. Ramadan repre-
sents a challenge to people with T2DM (or any other illness 
or handicap) who wish to fast. At the same time, it is also 
an opportunity for society, governments, nongovernmental 
organizations, and charities to cooperate, consolidate, and 
coordinate resources to reach out and provide help, counsel-
ing, and supplies, including nutritional and medicinal.
Health care providers and patients can benefit from 
information on the use of low-cost medications, including 
generic oral antidiabetic agents, human nonanalog insulin, 
and point-of-care capillary glucose monitoring. These are 
just a few examples of low-cost alternatives that can help 
ensure that no-one is deprived of their basic health care needs. 
Prior studies have shown that the overwhelming majority of 
Muslims with T2DM will fast during Ramadan, irrespective 
of medical advice.12 No effort should be spared to assist all 
those who wish to fast from doing so as safely and courte-
ously as possible.
Limitations
As discussed above, high-level evidence derived from 
randomized clinical trials evaluating currently available 
antidiabetic agents during Ramadan fasting are scarce. The 
available trial data are hence based on open-labeled studies 
of small sample size that are uniformly industry-sponsored. 
It follows that the opinions expressed in this review are of 
necessity based primarily on low-level trial evidence, pub-
lished expert opinion, and anecdotal personal experience. The 
need for high-level evidence, based on high-quality clinical 
trials in this field, cannot be overemphasized.
Conclusion
The overwhelming majority of Muslims with T2DM will 
insist on fasting for Ramadan. Health care providers need 
to address the risks associated with partial day fasting 
and provide the best individually tailored approaches. 
This can be achieved with knowledge and skills based on 
pathophysiological principles, trial evidence, expert opinion, 
the potential advantage of better post-Iftar glycemic control 
compared with a single long-acting or intermediate-acting 
basal preparation.
Twice-daily premixed (intermediate-acting) insulin
Twice-daily premixed insulin is the most commonly used 
insulin regimen by people with T2DM in several countries,49 
mostly due to patient convenience. Several studies have 
shown it to be just as efficacious in terms of glycemia control 
compared with more elaborate regimens, such as the more 
recently adopted basal-bolus regimen.50,51
Patients are advised to take the larger premixed insulin 
dose at Iftar. This dose can be augmented to cover antici-
pated higher post-Iftar glucose excursions. The smaller 
dose is taken at Suhur, with empiric reduction of the dose 
by 20%–30%. This should be adjusted during the month 
according to the daytime fasting glycemic levels. Whether 
the recently introduced and more costly analog mixed insulin 
preparations, eg, Humalog Mix 25 (25% short-acting insulin 
lispro and 75% intermediate-acting neutral lispro protamine, 
Eli Lilly) or biphasic insulin aspart 30 (short-acting insulin 
aspart and 70% intermediate-acting aspart, Novo Nordisk) 
are significantly better in terms of both glycemic control 
and lower hypoglycemia rates than the nonanalog insulin 
preparations, eg, Humulin M3 (Eli Lilly, human insulin 30% 
soluble, 70% isophane) and similar preparations from Novo 
Nordisk, sanofi-aventis, and other generic insulin preparation 
manufacturers, remains to be verified in the general nonfast-
ing and fasting patient populations.
A randomized, open-labeled, crossover study compared 
the analog premixed insulin Humalog Mix 25 (Eli Lilly) 
with the nonanalog premixed insulin Humulin M3 (Eli Lilly), 
and, given in identical doses, the analog preparation showed 
somewhat better postprandial blood glucose control after 
Iftar and lower rates of hypoglycemic events.52 The use of 
a Humalog Mix 50 (50% premixed lispro with 50% neutral 
protamine lispro, Eli Lilly) preparation at Iftar and a nonana-
log premixed 30:70 insulin preparation at Suhur (predawn 
meal) showed a modest reduction in postprandial glucose 
excursions and hypoglycemia rates compared with a twice-
nightly nonanalog premixed 30:70 insulin preparation.53
In the absence of clear and distinct advantages of the 
newer analog preparations, it is difficult to justify shifting 
patients from the well established, universally available, and 
cheaper nonanalog insulin preparations. However, adjust-
ment of Iftar insulin doses to contain more short-acting 
insulin deserves consideration.
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and experience. Success is more likely if the health care 
provider addresses and accommodates the personal health 
profile, cultural practices, and socioeconomic variables. 
Although hypoglycemia represents an imminent health 
risk, this can be minimized by structured Ramadan-focused 
diabetes education (for both the health care provider and 
patients) and medication adjustments (especially with 
respect to sulfonylureas and insulin). Similarly, drastic 
fluctuations in the glycemic profile (especially night-time 
hyperglycemia) can be avoided by appropriate pre-Ramadan 
assessment and counseling. Appropriate selection of tools 
for glycemic control until a steady glycemic state is achieved 
before Ramadan makes adjustments during fasting more 
efficacious. Safe fasting can be a reality with prudence and 
diligence by health care providers and can be facilitated by 
patient empowerment and support.
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